Related Experiment Video
Updated: May 19, 2026
12:37
Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
Resolution Pharmacology Targeting the Melanocortin System
Nicholas J Day1, Camilla S A Davan-Wetton1, Natalya Khodeneva1
1The William Harvey Research Institute, Queen Mary University of London, London, UK.
Current Topics in Microbiology and Immunology
|May 18, 2026
Summary
New research focuses on the body's natural inflammation resolution mechanisms. Targeting the melanocortin system offers novel drug development opportunities for chronic inflammatory diseases.
Area of Science:
- Immunology
- Pharmacology
- Drug Discovery
Background:
- Inflammation resolution is now understood as an active, coordinated process.
- This understanding shifts therapeutic focus towards endogenous pro-resolving mechanisms.
- The melanocortin system is a key endogenous pathway involved in inflammation resolution.
Purpose of the Study:
- To explore the therapeutic potential of targeting the melanocortin system.
- To review the development of novel molecules modulating the melanocortin system.
- To identify future research directions for melanocortin-based therapies.
Main Methods:
- Review of existing literature on inflammation resolution and the melanocortin system.
- Analysis of drug development efforts targeting melanocortin receptors.
- Synthesis of data on therapeutic applications and future research needs.
Main Results:
- The melanocortin system, comprising five G-protein-coupled receptors and endogenous peptides, plays a crucial role in resolving inflammation.
- Several melanocortin-based drugs are approved for treating inflammatory conditions like rheumatoid arthritis.
- Ongoing research aims to develop improved molecules for enhanced therapeutic efficacy.
Conclusions:
- Targeting the melanocortin system represents a promising strategy for treating chronic inflammatory diseases.
- Further development is needed to optimize melanocortin-based drug candidates.
- Exploiting the body's pro-resolving mechanisms offers a pathway to novel anti-inflammatory medicines.
Related Concept Videos
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:12GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.